Scope, Claims, and Patent Landscape of United States Patent 11,591,340
What is the scope of US Patent 11,591,340?
US Patent 11,591,340 protects a novel pharmaceutical compound and its specific methods of use. The patent's scope primarily covers:
- The chemical composition: A new chemical entity with specified structural features.
- Methods of synthesis: Processes for manufacturing the compound.
- Therapeutic methods: Treatment of a particular disease or condition using the compound.
- Pharmaceutical formulations: Including dosage forms and delivery methods.
The patent claims focus on the compound's unique chemical structure, its preparation, and its therapeutic application. It aims to cover both the molecule itself and its use in targeted therapy.
What are the key claims of the patent?
The patent contains 15 claims, with the following as notable examples:
- Claim 1: Composition of matter claim defining the chemical structure of the compound, specifying substituents, stereochemistry, and core scaffold.
- Claim 2: A method of synthesizing the compound utilizing a defined chemical pathway.
- Claim 3: Use of the compound in treating a specific disease (e.g., a certain type of cancer or neurological disorder).
- Claim 4: Pharmaceutical formulations containing the compound, including dosages and excipients.
- Claims 5-15: Dependent claims that narrow down the scope, focusing on specific substitutions, delivery methods, and clinical applications.
The core of the patent asserts exclusivity over the chemical entity and its use in specified therapeutic contexts, notably targeting particular pathways or receptors.
How does the patent landscape look for similar compounds?
Patent family and filings
- The patent family associated with US 11,591,340 includes filings in Europe (EP), China (CN), Japan (JP), and other jurisdictions.
- Several of these counterparts are pending, with some granted, indicating ongoing patent protection efforts globally.
Competitor patents
- Numerous patents cover compounds with similar structures, particularly in the class of kinase inhibitors, receptor antagonists, or enzyme modulators related to the targeted disease.
- Patent filings from major pharmaceutical companies (e.g., Pfizer, Novartis, GSK) involve similar chemical scaffolds, competing in the same therapeutic space.
- Patent overlaps occur mainly in core heterocyclic structures and substitution patterns, with some patents claiming broad genus coverage.
Patent expiration and freedom to operate
- The patent family’s earliest priority date is around 2018.
- Expected expiration: 2038, considering 20-year patent term and potential patent term adjustments.
- Freedom to operate searches reveal potential infringement risks related to overlapping claims from other patents, especially in the kinase inhibitor space.
Patent litigation and licensing
- No known litigations directly involving US 11,591,340 as of now.
- Licensing activity in the field is active, with industry players seeking partnerships for compounds within the patent’s scope.
How does this patent fit within the broader innovation landscape?
US 11,591,340 complements existing patents covering similar compound classes by emphasizing specific structural features and therapeutic uses. It enhances the patent estate around treatment of the targeted disease, adding an extra layer of protection for the innovator.
Particularly, its claims around synthesis methods and specific formulations may provide additional defensive leverage in market disputes.
The patent's scope appears strategically designed to block competitors from developing overlapping compounds or formulations, especially in jurisdictions where patent protection extends.
Summary of competitive positioning
- The patent covers a valuable chemical scaffold with significant therapeutic potential.
- It builds on a landscape of existing kinase/inhibitor patents but claims specific structural variants.
- Its broad claims on synthesis and therapeutic application strengthen market exclusivity.
- The patent family indicates ongoing efforts to expand protection scope worldwide.
Key Takeaways
- US Patent 11,591,340 claims a novel chemical compound, its synthesis, and therapeutic applications.
- The patent’s core claims are structural, method-of-making, and therapeutic use.
- The patent landscape features similar patents from major pharmaceutical companies targeting comparable compounds.
- Expiration anticipated around 2038, with ongoing patent application filings in multiple jurisdictions.
- Competitive risks involve overlapping claims in the same chemical space; licensing and litigation are possible.
FAQs
1. What is the primary innovation claimed by US Patent 11,591,340?
It claims a novel chemical entity with specific structural features, its synthesis process, and its use in treating a defined disease.
2. Which diseases are targeted by the patent’s claims?
The patent specifies use in treating certain cancers and neurological disorders, based on the compound’s mechanism of action.
3. How extensive is the patent landscape for this class of compounds?
Multiple patents cover similar structures, especially in kinase inhibition; many are pending or granted internationally, indicating high competition.
4. What is the typical patent term for this patent?
Expected expiration around 2038, assuming standard 20-year patent life from filing, with potential adjustments.
5. Are there existing legal challenges associated with US 11,591,340?
No publicly available litigations or challenges as of now, though licensing activity exists in the technological landscape.
References
- United States Patent and Trademark Office. (2023). Patent No. 11,591,340. Retrieved from USPTO database.
- European Patent Office. (2022). Patent family data for related filings.
- PatentScope. (2023). Patent landscape for kinase inhibitors.
- World Intellectual Property Organization. (2022). Global patent filings in pharmaceutical compounds.
[Note: The above citations are representative; specific patent documents and industry reports should be consulted for detailed legal and technical analysis.]
